BiotechTube

PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxel

Phase 3Terminated
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

Conditions

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

Trial Timeline

Jan 6, 2025 โ†’ Dec 23, 2025

NCT ID
NCT06038539

About PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxel

PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxel is a phase 3 stage product being developed by Biocon for HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients. The current trial status is terminated. This product is registered under clinical trial identifier NCT06038539. Target conditions include HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06038539Phase 3Terminated

Competing Products

20 competing products in HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
25
eFT508eFFECTOR TherapeuticsPhase 2
44
No drugDaiichi SankyoPre-clinical
23
ASP0113 + PlaceboAstellas PharmaPhase 2
52
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
52
EnzalutamideAstellas PharmaPhase 2
52
Cefiderocol + Standard of CareShionogiPhase 2
52
CefiderocolShionogiPre-clinical
23
Cefiderocol + Standard of CareShionogiPhase 2
52
Cefiderocol + Standard of CareShionogiPhase 2
52
E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
77
Durvalumab + EribulinEisaiPhase 1
33
Eribulin + Cyclophosphamide + DocetaxelEisaiPhase 2
52
eribulin mesylate + carboplatinEisaiPhase 2
52
Abemaciclib + BicalutamideEli LillyPhase 2
52
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
52
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
77
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
77
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
65

Other Products from Biocon

Stelara + Bmab1200Phase 3
77
EQ001 + EQ001 PlaceboPhase 3
77
Itolizumab + EQ001 PlaceboPhase 3
77
Humira 40 MG in Prefilled Syringe + Hulio 40 MG in Prefilled Syringe / Humira 40 MG in Prefilled SyringePhase 3
77
Bmab 1000 + ProliaยฎPhase 3
77